Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Allogeneic natural killer cells for refractory lymphoma.

Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS.

Cancer Immunol Immunother. 2010 Nov;59(11):1739-44. doi: 10.1007/s00262-010-0896-z. Epub 2010 Aug 3.

2.

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS.

Blood. 2014 Jun 19;123(25):3855-63. doi: 10.1182/blood-2013-10-532531. Epub 2014 Apr 9.

3.

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS.

Cytotherapy. 2011 Jan;13(1):98-107. doi: 10.3109/14653249.2010.515582. Epub 2010 Sep 20.

4.

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J Jr, Burns LJ.

Biol Blood Marrow Transplant. 1997 Apr;3(1):34-44.

PMID:
9209739
5.

Therapeutic applications: natural killer cells in the clinic.

Miller JS.

Hematology Am Soc Hematol Educ Program. 2013;2013:247-53. doi: 10.1182/asheducation-2013.1.247. Review.

PMID:
24319187
6.

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB.

Blood. 2005 Apr 15;105(8):3051-7. Epub 2005 Jan 4.

7.
8.

Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.

Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6101-10.

9.

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.

Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM.

Leuk Lymphoma. 2010 Jul;51(7):1241-50. doi: 10.3109/10428194.2010.486876.

PMID:
20496994
10.

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.

Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, Difrancesco A, Milan S, Wilson SE, Wolin M.

Clin Cancer Res. 2004 Apr 1;10(7):2253-64.

11.

Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.

Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL.

Clin Cancer Res. 1995 Jun;1(6):607-14.

12.

Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.

Lauria F, Raspadori D, Ventura MA, Rondelli D, Zinzani PL, Gherlinzoni F, Miggiano MC, Fiacchini M, Rosti G, Rizzi S, Tura S.

Bone Marrow Transplant. 1996 Jul;18(1):79-85.

PMID:
8831999
13.

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.

Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS.

Bone Marrow Transplant. 2003 Jul;32(2):177-86.

PMID:
12838283
14.

Ex vivo expansion of natural killer cells for clinical applications.

Klingemann HG, Martinson J.

Cytotherapy. 2004;6(1):15-22.

PMID:
14985163
15.

Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.

Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, Sprague KA, Miller KB, Comenzo RL, Kewalramani T, Yu N, Van Etten RA, McKenna DH.

Transfusion. 2013 Feb;53(2):412-8; quiz 411. doi: 10.1111/j.1537-2995.2012.03764.x. Epub 2012 Jun 28.

16.

Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation.

Katsanis E, Anderson PM, Filipovich AH, Hasz DE, Rich ML, Loeffler CM, Ochoa AC, Weisdorf DJ.

Blood. 1991 Sep 1;78(5):1286-91.

17.
18.

Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.

Choi I, Yoon SR, Park SY, Kim H, Jung SJ, Jang YJ, Kang M, Yeom YI, Lee JL, Kim DY, Lee YS, Kang YA, Jeon M, Seol M, Lee JH, Lee JH, Kim HJ, Yun SC, Lee KH.

Biol Blood Marrow Transplant. 2014 May;20(5):696-704. doi: 10.1016/j.bbmt.2014.01.031. Epub 2014 Feb 11.

19.

A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors.

Pérez-Martínez A, Fernández L, Valentín J, Martínez-Romera I, Corral MD, Ramírez M, Abad L, Santamaría S, González-Vicent M, Sirvent S, Sevilla J, Vicario JL, de Prada I, Diaz MÁ.

Cytotherapy. 2015 Nov;17(11):1594-603. doi: 10.1016/j.jcyt.2015.07.011. Epub 2015 Sep 1.

PMID:
26341478
20.

Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation.

Pascal V, Brunet C, Pradel V, Thirion X, Andre P, Faucher C, Sampol J, Dignat-George F, Blaise D, Vivier E, Chabannon C.

Leukemia. 2002 Nov;16(11):2259-66.

Supplemental Content

Support Center